Multiple sclerosis (MS) can cause significant physical impairment, including fatigue, pain, muscle spasms, tremors and dizziness. For many with MS, the disease wreaks havoc with emotional well-being, too, and according to a new study, minorities might especially be at risk for developing...
New research findings appearing in the January Journal of Lipid Research indicate that compounds called oxysterols are not present in any significant amount in multiple sclerosis patients, contradicting a previous study that suggested that some of these cholesterol metabolites were associated...
BioTrends recently published TreatmentTrends®: Multiple Sclerosis, a syndicated biannual report that provides a comprehensive view of the current and expected future management of multiple sclerosis (MS) based on primary research fielded with 103 neurologists in the U.S. A parallel report...
The Food and Drug Administration (FDA) has extended the review period for Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis by another three months, to give time for a comprehensive review of additional information under the NDA (new drug application), Merck KGaA...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and...
Scientists are reporting what they say is compelling evidence that some powerful non-heritable, environmental factor likely plays a key role in the development of multiple sclerosis. Their finding, the cover article in the April 29, 2010 issue of Nature, results from the most advanced genomic...
The U.S. Food and Drug Administration approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the...
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2). The...
The U.S. Food and Drug Administration approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the...
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2). The...
Adeona Pharmaceuticals, Inc., (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced that the ongoing clinical trial of its Trimesta™ (oral estriol) drug...
I tested positive for an autoimmune disease 2 years ago. My Dr. referred me to a Rheumatologist who diagnosed me with Lupus and Rheumatoid Arthritis. The problem is none of my medications are helping and I feel worse now than ever. I have started having trouble with walking (I walk like a...
I'm 14 turning 15 in October, and from what I've read on wikipedia and other sites, I think I may have MS. Can someone please explain to me the symptoms, and the method of diagnosis if it is possible I have MS?